Smart Medicine (Sep 2024)

Engineering strategies for apoptotic bodies

  • Zheyuan Hu,
  • Shutong Qian,
  • Qiuyu Zhao,
  • Bolun Lu,
  • Qian Lu,
  • Yuhuan Wang,
  • Liucheng Zhang,
  • Xiyuan Mao,
  • Danru Wang,
  • Wenguo Cui,
  • Xiaoming Sun

DOI
https://doi.org/10.1002/SMMD.20240005
Journal volume & issue
Vol. 3, no. 3
pp. n/a – n/a

Abstract

Read online

Abstract Extracellular vesicles (EVs) are lipid bilayer vesicles containing proteins, lipids, nucleic acids, and metabolites secreted by cells under various physiological and pathological conditions that mediate intercellular communication. The main types of EVs include exosomes, microvesicles, and apoptotic bodies (ABs). ABs are vesicles released during the terminal stages of cellular apoptosis, enriched with diverse biological entities and characterized by distinct morphological features. As a result, ABs possess great potential in fields like disease diagnosis, immunotherapy, regenerative therapy, and drug delivery due to their specificity, targeting capacity, and biocompatibility. However, their therapeutic efficacy is notably heterogeneous, and an overdose can lead to side effects such as accumulation in the liver, spleen, lungs, and gastrointestinal system. Through bioengineering, the properties of ABs can be optimized to enhance drug‐loading efficiency, targeting precision, and multifunctionality for clinical implementations. This review focuses on strategies such as transfection, sonication, electroporation, surface engineering, and integration with biomaterials to enable ABs to load cargoes and enhance targeting, providing insights into the engineering of ABs.

Keywords